Key Highlights

  • PRCT shares are trading down 6.55% to $21.27.
  • Multiple law firms are racing toward a September 22, 2026 lead plaintiff deadline in a federal class action.
  • The lawsuit alleges the company masked weakening handpiece Demand through an undisclosed bulk-discount program that pulled forward sales.
  • The complaint alleges customers were left overstocked with more than 10,000 excess units.
  • Investors are also digesting a fresh fiduciary-duty investigation into company officers and directors.

Shares Fall as Litigation Deadline Approaches

PROCEPT BioRobotics (NASDAQ:PRCT) shares are tumbling as mounting securities litigation continues to overhang the stock, with multiple law firms racing toward a September 22, 2026 lead plaintiff deadline in a federal class action. PROCEPT is a commercial-stage surgical robotics company focused on developing image-guided solutions for minimally invasive urologic surgery, with its flagship AquaBeam and HYDROS Robotic Systems delivering proprietary Aquablation therapy.

Lawsuit Alleges an Undisclosed Bulk-Discount Program

The lawsuit alleges the company masked weakening handpiece demand through an undisclosed bulk-discount program that pulled forward sales, leaving customers overstocked with more than 10,000 excess units. PROCEPT generates Revenue through an installed-base model, selling Capital equipment alongside recurring procedure-linked disposable handpieces to hospitals and surgical centers.

Fresh Fiduciary-Duty Investigation Adds to Pressure

Investors are also digesting a fresh fiduciary-duty investigation into company officers and directors, adding to concerns over previously reported handpiece unit growth figures and whether the company's 2025 guidance lacked a reasonably achievable basis. Those overlapping legal concerns appear to be the primary driver of today's decline.

Broader Market Weakness Adds to the Pressure

The stock's decline today, on below-average volume, comes amid a broader risk-off tone across healthcare and technology stocks as oil prices near $100 and rate-hike fears build ahead of key Inflation data. The September 22 lead plaintiff deadline and any further disclosures from the fiduciary-duty investigation will likely remain the key overhangs for the stock in the weeks ahead.